PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26193343-3	2015	We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling.	ibrutinib	69-78	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	21-24	
33946867-0	2021	Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.	ibrutinib	91-100	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	115-118	
33946867-5	2021	In this study, we explored for the first time the metabolic regulators of ibrutinib-resistant activated B-cell (ABC) DLBCL using a multi-omics analysis that integrated metabolomics (using high-resolution mass spectrometry) and transcriptomic (gene expression analysis).	ibrutinib	74-83	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	112-115	
33856277-2	2021	Ibrutinib and lenalidomide are synergistic in vitro in ABC DLBCL and may augment salvage chemotherapy.	ibrutinib	0-9	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	55-58	
28592763-4	2017	Ibrutinib or lenalidomide was shown to be more effective in activated B-cell (ABC) -type-DLBCL than in germinal center B-cell type-DLBCL.	ibrutinib	0-9	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	78-81	
27904766-0	2016	The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.	ibrutinib	24-33	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	44-47	
27904766-6	2016	A phase 1/2 clinical trial of single-agent ibrutinib in relapsed and refractory DLBCL patients revealed an overall response rate of 37% in ABC-DLBCL patients.	ibrutinib	43-52	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	139-142	
27904766-8	2016	Here we report the discovery of point mutations within the kinase PIM1 that reduce sensitivity to ibrutinib in ABC-DLBCL.	ibrutinib	98-107	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	111-114	
27904766-10	2016	The introduction of mutant PIM1 into an ABC-DLBCL cell line, TMD8, increased colony formation and decreased sensitivity to ibrutinib.	ibrutinib	123-132	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	40-43	
26193343-4	2015	In a phase 1/2 clinical trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106).	ibrutinib	91-100	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	169-172	
26193343-7	2015	These results support the selective development of ibrutinib for the treatment of ABC DLBCL.	ibrutinib	51-60	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	82-85	
22698399-5	2012	Blockade of B cell receptor signaling using the BTK inhibitor ibrutinib also downregulates IRF4 and consequently synergizes with lenalidomide in killing ABC DLBCLs, suggesting attractive therapeutic strategies.	ibrutinib	62-71	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	153-156